A pCR of the CLN (cN+ to pN0 conversion) was noted in 41 patients (50.6%) with the following tumor markers: 18.8% of HR+/HER2−, 75% of HR+/HER2+, 75% of HR−/HER2+, and 62.5% of triple-negative (p-value = 0.006) (Table 3). This evidence concerns the gene ERBB2 and neoplasm.